Two-year outcome after early or late Intervention in non-ST elevation acute coronary syndrome by Badings, E.A. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/182932
 
 
 
Please be advised that this information was generated on 2018-04-11 and may be subject to
change.
 1Badings EA, et al. Open Heart 2017;4:e000538. doi:10.1136/openhrt-2016-000538
To cite: Badings EA,  Remkes 
WS, The SHK, et al. Two-
year outcome after early or 
late Intervention in non-ST 
elevation acute coronary 
syndrome. Open Heart 
2017;4:e000538. doi:10.1136/
openhrt-2016-000538
Received 14 September 2016
Revised 5 December 2016
Accepted 10 January 2017
1Department of Cardiology, 
Deventer Ziekenhuis, Deventer, 
Netherlands
2Department of Cardiology, Isala 
klinieken, Zwolle, Netherlands
3Department of Cardiology, 
Treant Zorggroep locatie 
ziekenhuis Bethesda, 
Hoogeveen, Netherlands
4Department of Cardiology, 
Ziekenhuis De Tjongerschans, 
Heerenveen, Netherlands
5Department of Cardiology, 
Maastricht UMC, Maastricht, 
Netherlands
6Department of Cardiology, 
Atrium Medisch Centrum, 
Heerlen, Netherlands
7Department of Cardiology, 
Radboudumc, Nijmegen, 
Netherlands
Correspondence to
Dr Arnoud WJ van ’t Hof, 
Isala Klinieken, Department 
of Cardiology, Dokter van 
Heesweg 2 8025 AB Zwolle, The 
Netherlands;  a. w. j. vant. hof@ 
isala. nl
Two-year outcome after early or late 
Intervention in non-ST elevation acute 
coronary syndrome
Erik A Badings,1 Wouter S Remkes,2 Salem H K  The,3 Jan-Henk E Dambrink,2 
Geert Tjeerdsma,4 Saman Rasoul,5,6 Jorik R Timmer,2 Marloes L J van der Wielen,3 
Dirk J A  Lok,1 Renicus S  Hermanides,2 Jan  Van Wijngaarden,1 
Harry Suryapranata,2,7 Arnoud W J  van ’t Hof2
ABSTRACT
Objective To compare long-term outcome of an early to a 
delayed invasive strategy in high-risk patients with non-ST 
elevation acute coronary syndrome (NSTE-ACS).
Methods This prospective, multicentre trial included 
patients with NSTE-ACS and at least two out of three of 
the following high-risk criteria: (1) evidence of extensive 
myocardial ischaemia on ECG, (2) elevated biomarkers 
for myocardial necrosis and (3) age above 65 years. 
Patients were randomised to either an early (angiography 
and revascularisation if appropriate <12 hours) or a 
delayed invasive strategy (>48 hours after randomisation). 
Endpoint for this prespecified long-term follow-up was the 
composite incidence of death or reinfarction after 2 years. 
Data collection was performed by telephone contact with 
the patients, their relatives or general practitioner and by 
review of hospital records.
Results Endpoint status after 2-year follow-up was 
collected in 521 of 542 initially enrolled patients. Incidence 
of death or reinfarction was 11.8% in the early and 13.1% 
in the delayed treatment group (relative risk (RR)=0.90, 
95% CI 0.57 to 1.42). No significant differences were 
found in occurrence of the individual components of 
the primary endpoint: death 6.1% vs 8.9%, RR 0.69 
(95% CI 0.37 to 1.27), reinfarction 6.5% vs 5.4%, RR 
1.20 (95% CI 0.60 to 2.38). Post-hoc subgroup analysis 
showed statistical significant interaction between age and 
treatment strategy on outcome (p=0.02).
Conclusions After 2 years follow-up, no difference in 
incidence of death or reinfarction was seen between 
early to late invasive strategy. These findings are in 
line with results of other studies with longer follow-up. 
Older patients seem to benefit more from early invasive 
treatment.
INTRODUCTION
Although numerous trials have investigated 
the outcome of an early versus a delayed 
invasive treatment strategy in patients with 
non-ST elevation acute coronary syndrome 
(NSTE-ACS), controversy remains about the 
optimal timing of angiography and revas-
cularisation in this patient group. Several 
meta-analyses1–5 pooled the results of these 
trials to systematically address this question. 
The main conclusion is that early interven-
tion results in a reduction of the incidence of 
recurrent ischaemia and duration of hospital 
stay but not in mortality or reinfarction. 
Based on these results, current guidelines 
recommend intervention within 24 hours in 
NSTE-ACS patients with one or more high-
risk criteria.6
Follow-up in the majority of the above-men-
tioned trials has been limited to one to 
several months. However, long-term clinical 
outcome is essential to decide about the 
optimal timelines of intervention in these 
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KEY QUESTIONS
What is already known about this subject?
 ► Early intervention in patients with non-ST elevation 
acute coronary syndrome (NSTE-ACS) results in a 
reduction of the incidence of recurrent ischaemia 
and duration of hospital stay but not in mortality 
or reinfarction after one or several months. Little 
is known of the effect on clinical endpoints after 
longer follow-up.
What does this study add?
 ► This prespecified analysis of the ELISA-3 trial 
(trial registration number ISRCTN39230163) 
after 2-year follow-up showed no difference in 
incidence of death or  reinfarction between early 
to late invasive strategy. Exploratory subgroup 
analysis showed that very elderly patients seem to 
benefit more from early invasive treatment.
How might this impact on clinical practice?
 ► Considering comparable clinical outcome after 
short-term and long-term follow-up, no adjustment 
of the current non-ST-Segment elevation 
myocardial infarction guideline is necessary in 
timing of intervention in patients with NSTE-ACS. 
In daily practice, older patients often undergo 
angiography relatively late after admission. Our 
long-term trial results suggest that older age 
patients should rather be considered for early 
angiography, but this needs further investigation.
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patients. In this publication we present the results of the 
prespecified analysis after 2-year follow-up of the ELISA-3 
trial, an investigator initiated a randomised, open, multi-
centre study comparing early versus late angiography and 
revascularisation in high-risk patients with NSTE-ACS.
METHODS
The design and the results at 30-day follow-up of the 
ELISA-3 trial have been published previously.7 In short, 
patients were eligible if they were hospitalised with isch-
aemic chest pain or dyspnoea at rest and had at least 2 out 
of 3 of the following high-risk characteristics: (1) evidence 
of extensive myocardial ischaemia on ECG (shown by 
new cumulative ST depression >5 mm or temporary 
ST segment elevation in two contiguous leads <30 min), 
(2) elevated biomarkers (troponin T>0.10 µg/L or 
myoglobin >150 µg/L) or elevated creatine kinase-myo-
cardial band (CKMB) fraction (>6% of total creatine 
kinase (CK)) and (3) age above 65 years. Randomisation 
had to take place within 24 hours of the last episode of 
ischaemic symptoms. Exclusion criteria were persistent ST 
segment elevation, symptoms of ongoing myocardial isch-
aemia despite optimal medical therapy, contraindication 
for diagnostic angiography, active bleeding, cardiogenic 
shock, acute posterior infarction and life expectancy 
less than 1 year. Patients were 1:1 randomly assigned by 
a web-based randomisation system to an early treatment 
strategy (angiography and subsequent revascularisation 
as soon as possible but within 12 hours of randomisation) 
or a delayed treatment strategy (no sooner than 48 hours 
after randomisation). The primary endpoint was the 
combined incidence of death, reinfarction and/or recur-
rent ischaemia at 30-day follow-up. Follow-up for 2 years 
after the index event for incidence of mortality or rein-
farction was pre-specified in the protocol. Patients were 
contacted by telephone to collect information about vital 
status and potential endpoints. If patients could not be 
contacted by telephone, their relatives or general prac-
titioner was contacted to obtain information. In case of 
re-hospitalisation, hospital records were reviewed.
Data were analysed according to the intention to 
treat principle. Continuous variables were expressed as 
median and first and third quartiles, and were compared 
between the intervention groups using a Mann-Whitney 
U test. Categorical data were described by proportions 
and compared with the χ2 test or Fisher exact test. Logistic 
regression was used to calculate the p-value of the inter-
action between the effect of the intervention and the 
subgroups on the primary endpoint. All tests were 
two sided, and an alpha of 5% was used. Statistical anal-
ysis was performed with SPSS (V.20). Cumulative event 
rates were estimated with the Kaplan-Meier method and 
compared with log-rank test.
The study complied with the Declaration of Helsinki, 
was approved by the ethics committee of the Isala 
Klinieken, Zwolle, The Netherlands, and was registered 
in the ISRCTN Register (ISRCTN39230163). More 
information about this trial can be found on the website 
http://www. isrctn. com 
RESULTS
Between July 2007 and June 2012, 542 patients were 
included in six Dutch hospitals of which one had 
24 hours facilities for (primary) percutaneous coronary 
intervention (PCI) and coronary arterial bypass graft. 
Eight patients were excluded. Two hundred and sixty-
nine patients were randomised to early invasive strategy 
and 265 to delayed invasive strategy (figure 1). Baseline 
characteristics were well balanced between the groups 
(table 1).
Median time from admission to randomisation was 
2.0 hours in the immediate group and 2.1 hours in the 
delayed treatment group (p=0.97); median interval 
between randomisation and angiography was 2.6 hours 
and 54.9 hours, respectively (p<0.001). Pharmacological 
therapy after 30 days and one- and two-year follow-up 
is shown in table 2 and was comparable between both 
treatment groups. The use of medication for secondary 
prevention was high; almost all patients not treated with 
oral anticoagulants used aspirin, and over 80% used 
beta blockers and statins.
The original publication of the ELISA-3 trial showed 
a non-significant reduction of 30% in the early invasive 
treated patients on the primary composite endpoint of 
death, reinfarction or recurrent ischaemia after 30-day 
follow-up.7 Median duration of hospitalisation in this 
group was statistically significant shorter (4 days, vs 6 
days in the late treatment group). Two-years follow-up 
could be performed in 521 patients, 96% of the initially 
enrolled patients. The cumulative incidence of death or 
reinfarction after 2-years follow-up did not differ signifi-
cantly (figure 2; log rank test p=0.67). This combined 
endpoint occurred in 11.8% of patients in the the early 
invasive group and 13.1% in the delayed treatment group 
(relative risk (RR)=0.90, 95% CI 0.57 to 1.42, table 3). 
No significant differences were found in the occurrence 
of the individual components of the primary endpoint: 
the rate of death (6.1% vs 8.9%, RR 0.69, 95% CI 0.37 to 
1.27) and recurrent myocardial infarction (6.5% vs 5.4%, 
RR 1.20, 95% CI 0.60 to 2.38).
Results of prespecified and post-hoc subgroup analysis 
are shown in figures 3 and 4, respectively. Only statistical 
significant interaction was found between age group 
(above vs below median age of 71.9 years) and treat-
ment strategy on outcome (p=0.022). In the 50% oldest 
patients, the combined endpoint occurred in 13.6% 
of patients in the early intervention as compared with 
21.7% of those in the delayed intervention group. For the 
patients aged under 71.9 years, the combined endpoint 
occurred in 10% and 4.6%, respectively.
DISCUSSION
These long-term follow-up results of the ELISA-3 trial 
show that in high-risk patients with NSTE-ACS, early 
angiography and revascularisation (median 2.6 hours 
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Figure 1 Trial flow chart.
Table 1 Patient baseline characteristics
Variable
Immediate treatment
n=269
Delayed treatment
n=265
Demographics
  Age (y; med, Q1–3) 72.1 (65.5–78.4) 71.8 (62.5–78.4)
  Male gender, n (%) 187 (69.5) 174 (65.7)
Randomised in (%)
  PCI centre 83.3 83.0
  Non-PCI centre 16.7 17.0
Grace score (med, Q1–3) 136 (118–154) 133 (117–154)
Medical history, n (%)
  Hypertension 146 (54.3) 154 (58.1)
  Smoking 57 (21.2) 70 (26.4)
  Diabetes mellitus 64 (23.8) 54 (20.4)
  Previous MI 48 (17.8) 52 (19.6)
  Previous TIA 15 (5.6) 13 (4.9)
  Previous stroke 9 (3.3) 12 (4.5)
Previous coronary procedures, n (%)
  Previous PCI 49 (18.2) 55 (20.8)
  Previous CABG 37 (13.8) 32 (12.1)
CABG, coronary arterial bypass graft; med, median; MI, myocardial infarction; PCI, percutaneous coronary intervention; Q1-3, 1st and 3rd 
quartile; TIA, transient ischaemic attack; y, years.
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Table 2 Medication therapy after 30 days, 1- and 2-year follow-up in early and late intervention group
30 days 1 year 2 years
Early
n=262 (%)
Late
n=261 (%)
Early
n=262 (%)
Late
n=259 (%)
Early
n=262 (%)
Late
n=259 (%)
Aspirin 84.0 84.8 79.4 80.0 78.8 75.1
Clopidogrel 67.2 64.6 42.6 46.7 11.0 10.5
Anticoagulance 14.4 15.2 20.1 14.6 19.2 18.6
Beta blocker 91.2 91.8 83.5 87.1 81.2 83.1
ACE inhibitors 62.0 56.8 62.7 50.8 55.5 49.4
AII-receptor blocker 12.4 11.5 18.5 18.8 19.6 19.0
Statin 90.0 88.1 87.6 85.8 85.3 81.9
Calcium blocker 20.4 22.6 24.1 26.3 25.7 25.7
Nitrate 14.1 17.3 18.1 20.8 18.4 16.9
Figure 2 Kaplan-Meier curve for event free survival of 
primary endpoint.
after admission) is not better than intervention 48 hours 
or more after admission in terms of mortality or reinfarc-
tion after a 2-year follow-up. Considering the results after 
30-day follow-up, in which we found a non-significant 
reduction of 30% (p=0.135) on the combined endpoint 
of mortality, reinfarction or recurrent ischaemia, effects 
of timing of intervention on short-term and long-term 
clinical outcome are comparable.
Only a few other studies described the long-term effects 
of timing of intervention in patients with NSTE-ACS. 
The SICCA trial,8 comparing early versus delayed inva-
sive strategy in high-risk NSTE-ACS patients reported 
only mortality after 4 years as secondary endpoint, which 
was equal in both treatment arms. The OPTIMA trial9 
recently reported 5-year outcome in NSTE-ACS patients 
after immediate versus deferred PCI and found no differ-
ences in the primary composite endpoint of death and 
spontaneous myocardial infarction (MI) but an increased 
risk of late spontaneous MI for patients treated with 
immediate PCI. We could not confirm this finding, but 
the studies are difficult to compare because of difference 
in patient population due to the fact that in the OPTIMA 
trial, patients were only randomised after coronary 
angiography, excluding patients not feasible for PCI or 
without significant coronary stenosis. Potential mecha-
nisms of excess of MI in the immediate PCI group could 
be an increased risk of malpositioning and improper 
stent sizing or stenting of non-significant lesions due to 
overestimating of lesion severity in the acute setting.
One publication reported long-term outcome after 
early or delayed angiography in patients with NSTE-ACS 
undergoing a routine invasive management.10 In this 
post-hoc collaborative analysis of individual patient data 
from three trials comparing routinely versus selective inva-
sive strategy, relationship between timing and outcome of 
patients originally randomised to the routine invasive arm 
of the trials was investigated. No difference in incidence 
of cardiovascular mortality or myocardial infarction after 
5-year follow-up was found between early (within 2 days) 
or delayed (within 3–5 days) angiography in the routinely 
invasive treatment arm. Because timing of intervention 
was not randomised, these results might have been biased 
by unequal distribution of prognostic factors associated 
with timing of angiography. Also, the timing of the early 
angiography group in this study was comparable with that 
of the late treatment strategy of the ELISA-3 trial.
Although methodological differences between studies 
are hampering the interpretation of results, overall 
these findings are in line with our results, showing no 
clear benefit of early invasive treatment strategy in terms 
of mortality or re-infarction in short and longer term. 
This is confirmed by all published meta-analyses on 
this topic1–5 showing that early intervention—despite 
the large number of patients included—only results in 
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Table 3 Study endpoints after 30-day and 2-year follow-ups
Variable
Immediate 
treatment
Delayed 
treatment RR (95% CI)
p 
Value
30-day follow-up n=262 (%) n=261 (%)
Combined incidence of death, reinfarction and recurrent ischaemia 9.9 14.2 0.70 (0.43 to 1.12) 0.14
  Death 1.1 1.1 1.00 (0.20 to 4.89) >0.99
  Reinfarction 1.9 0.8 2.49 (0.49 to 12.72) 0.45
  Recurrent ischaemia 7.6 12.6 0.60 (0.36 to 1.02) 0.06
2-year follow-up n=262 (%) n=259 (%)
Combined incidence of death or reinfarction 11.8 13.1 0.90 (0.57 to 1.42) 0.66
  Death 6.1 8.9 0.69 (0.37 to 1.27) 0.23
  Reinfarction 6.5 5.4 1.20 (0.60 to 2.38) 0.60
RR, relative risk.
Figure 3 Forest plot of relative risk of primary endpoint at 2 years in pre-specified patient subgroups. Data are number 
or number (%), unless otherwise indicated. Percentages are number of events divided by number of patients. Squares and 
horizontal bars represent within-subgroup relative risk and 95% CIs, respectively, on a log scale. Median pro-BNP=659 pg/mL. 
Median TropT=0.30 ng/mL.
a statistically significant reduction of the incidence of 
recurrent ischaemia and duration of hospital stay, but not 
in mortality or re-infarction. Therefore, the basis of the 
I-A indication for early invasive strategy (<24 hours) for 
NSTE-ACS patients with at least one high-risk criterion 
in the guidelines of the European Society of Cardiology 
for management of NSTE-ACS6 is somewhat questionable 
and puts a heavy burden on the capacity of cardiac cath-
eterisation facilities.
Subgroup analysis
Of all trials comparing early versus later intervention 
in NSTE-ACS, the ELISA-3 included the oldest patient 
population with a median age of 72 years. We found a 
significant interaction between the age and treatment 
strategy and on the primary endpoint (figure 4). This 
means that in this relatively old population, in the oldest 
half aged over 72 years, the benefit of early intervention 
was more pronounced than in the youngest half. Other 
trials comparing early versus delayed intervention that 
performed subgroup analysis did not find this interac-
tion with age.11–14 Although results of subgroup analysis 
should always be taken with caution, this finding is rele-
vant because in clinical practice, elderly patients with 
NSTE-ACS less often receive aggressive invasive care 
treatment due to fear for complications with catheterisa-
tion and revascularisation procedures.15 16 Despite more 
comorbidities, polypharmacy and physical frailty in this 
group of patients, a routine invasive treatment has shown 
to be superior over a selective invasive strategy.16–18 Future 
studies or meta-analysis of data in elderly patients are 
needed to investigate the value of early angiography and 
revascularisation, if indicated.
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Figure 4 Forest plot of relative risk of primary endpoint at 2 year in ad hoc selected patient subgroups. Data are number 
or number (%), unless otherwise indicated. Percentages are number of events divided by number of patients. Squares and 
horizontal bars represent within-subgroup relative risk and 95% CIs, respectively, on a log scale. Median age=71.9 years.
Limitations
Our study has some limitations. The study was not 
powered to detect a difference in death or MI at 2-year 
follow-up. Furthermore, the data for the 2-year follow-up 
were collected by contacting patients or their general 
practitioner by telephone and review of hospital records 
in case of rehospitalisation. This might have led to 
under-reporting of endpoints. Also, two patients were 
lost to follow up. Furthermore, the guidelines for treat-
ment of patients with NSTE-ACS have changed since this 
trial that was performed between 2007 and 2012. For 
example, we did not use high-sensitive troponin assays, 
and patients were treated with clopidogrel instead of 
ticagrelor, which is now standard of care. This might 
influence the external validity of our results. Therefore, 
a new, adequately powered trial using contemporary 
diagnostic and therapeutic strategies on this topic is 
needed.
In conclusion, in patients with high-risk NSTE-ACS, we 
found that an immediate invasive strategy is not superior 
to a delayed invasive strategy in terms of incidence of the 
composite endpoint of death or reinfarction at 2-year 
follow-up. However, shorter hospital stay and possibly 
lower costs are in favour of early intervention. Further-
more, older patients seem to benefit more from early 
invasive treatment.
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